Therapeutic applications of cytokines for immunostimulation and immunosuppression: An update

Progress in Drug Research

Volumn 47, Issue , 1996, Pages 211-250

  Cardi, Gaetano ^a   Ciardelli, Thomas L ^b,c   Ernstoff, Marc S ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOTOXIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

CANCER; DRUG MANUFACTURE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 0029803178     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0348-8998-8_6     Document Type: Review

References (256)

1. B. Lee and T. L. Ciardelli: Clinical applications of cytokines for immunostimulation and immunosuppression. Prog. in Drug Res. 39, 167 (1992).
2. T. Vail and J. Descotes: Immune-mediated side-effects of cytokines in humans. Toxicology 105, 31 (1995).
3. M.A.S. Moore: Hematopoietic reconstruction: New approaches. Clin. Cancer Res. 1, 3 (1995).
4. M.J. George:The present and future of hematopoietic cytokines in clinical practice. Stem Cells (Dayt) 12 S1., 249 (1994).
5. P.J. Quesenberry: Biotherapy in hematology:The next decade. Rev. Invest. Clin. Apr. S., 8 (1994).
6. F. Takaku: Clinical application of cytokines for cancer treatment. Oncology 51, 123 (1994).
7. R. Mertelsmann: Hematopoietic cytokines: from biology and pathophysiology to clinical application. Leukemia 7 S2, 168 (1993).
8. G.M. Clore, P.T. Wingfield and A.M. Gronenborn: High-resolution three-dimensional structure of interleukin 1 beta in solution by three- and four-dimensional nuclear magnetic resonance spectroscopy. Biochemistry 30, 2315 (1991).
9. K. Ye, K.C. Koch, B.D. Clark and C.A. Dinarello: Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression. Immunology 75, 427 (1992).
10. J. Smith, W. Urba, R. Steis, J. Janik et al.: Interleukin-1 alpha: Results of a phase one toxicity and immunomodulatory trial. Am. Soc. Clin. Oncol. 9, 717 (1990).
11. C.A. Haworth, N.M. Ravindir and M. Feldman, Prospects for cytokines in human immunotherapy.The cytokine handbook (Academic Press, 1994).
12. C.A. Dinarello and S.M. Wolff: The role of interleukin-1 in disease. N. Engl. J. Med. 325, 106 (1993).
13. C.A. Dinarello: The interleukin-1 family:10 years of discovery. FASEB J. 8, 1314 (1994).
14. C.A. Dinarello: Interleukin-1. Adv. in Pharm. 25, 21 (1994).
15. B.G. Redman, Y. Abubakr, T. Chou et al: Phase II trial of recombinant interleukin-1 beta in patients with metastatic renal cell carcinoma. J. Immunother. Emphasis Tumor Immunol. 16, 211 (1994).
16. P.L. Triozzi, J.A. Kim, E.W. Martin et al: Phase I trial of escalating doses of interleukin-1β in combination with a fixed dose of interleukin-2. J. Clin. Oncol. 13, 482 (1995).
17. J. Crown, A. Jakubowski and J. Gabrilove: Interleukin-1 : biological effects in human hematopoiesis. Leuk. Lymphoma 9, 433 (1993).
18. J.W. Smith 2nd, W.J. Urba, B.D. Curti et al.: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 10, 1141 (1992).
19. D. Weisdorf, E. Katsanis, C. Verfaillie et al.: Interleukin-1 alpha administered after autologous transplantation. Blood 84, 2044 (1994).
20. C.A. Dinarello: Blocking interleukin-1 receptors. Int. J. Clin. Lab. Res. 24, 61 (1994).
21. W.P. Arend: Interleukin-1 antagonism in inflammatory disease. Lancet 16, 155 (1993).
22. P. Ghiara, D. Armellini, G. Scapigliati et al.: Biological role of the IL-1 receptor type II as defined by monoclonal antibody. Cytokine 3, 1423 (1991).
23. C.A. Jacobs, M.P. Beckman, K. Mohler et al.: Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Internat. Rev. Exp. Path. 34, 123 (1993).
24. S.P. Eisenberg, R.J. Evans, W.P. Arend et al.: Primary structure and functional expression from complementary DNA of a human interleukin-1 antagonist. Nature 25, 341 (1990).
25. C.H. Hannum, C.J. Wilcox, W.P. Arend et al.: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343, 336 (1990).
26. E.V. Granowitz, R. Porat, J.W. Mier et al.: Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4, 353 (1992).
27. M.D. Mitchell, S.S. Edwin, R.M. Silver and R.J. Romero: Potential agonist action of the interleukin-1 receptor antagonist protein: implications for the treatment of women. J. Clin. Endocrin. Metab. 76, 1386 (1993).
28. J.H. Antin, H.J. Weinstein, E.C. Guinan et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of steroid resistant graft-versus-host disease. Blood 84, 1342 (1994).
29. E. Abraham and T.A. Raffin: Sepsis Therapy Trial. JAMA 271, 1876 (1994).
30. C.J. Fisher, J.A. Dhainaut, S.M. Opal et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271, 1836 (1994).
31. S.A. Greenfeld, P. Nunes, L. Kwee et al.: Molecular cloning and characterization of a second subunit of the interleukin-1 receptor. J. Biol. Chem. 270, 13757 (1995).
32. K.A. Smith: Interleukin-2: Inception, impact and implications. Science 240, 1169 (1988).
33. Y. Minami, T. Kono, T. Miyazaki and T. Taniguchi: The IL-2 receptor complex. Annu. Rev. Immunol. 11, 245 (1993).
34. T. Taniguchi and Y. Minami: The IL-2/IL-2 receptor system: a current overview. Cell 73, 5 (1993).
35. J.N. Ihle: Cytokine receptor signalling. Nature 377, 591 (1995).
36. c Chains with Jak1 and Jak3: Implications for XSCID and XCID. Science 266, 1042 (1994).
37. B.A. Witthuhn, O. Silvennoinen, O. Miura et al.: Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370, 153 (1994).
38. T. Miyazaki, A. Kawahara, H. Fujii et al.: Functional Activation of Jak1 and Jak3 by Selective Association with IL-2 Receptor Subunits. Science 266, 1045 (1994).
39. N. Stahl and G.D. Yancopoulos: The Alphas, Betas, and Kinases of Cytokine Receptor Complexes. Cell 74, 587 (1993).
40. S.M. Gorsch and M.S. Ernstoff: Management of Metastatic Renal Cell Carcinoma: Chemotherapy. Hormonal Therapy and Interferons. In: Comprehensive Textbook of Genitourinary Oncology. N.J. Vogelzang, P.T. Scardino, W.U. Shipley and D.S. Coffey (eds). Williams & Wilkins, Baltimore (1996).
41. J.K. Bruton and J.M. Koeller: Recombinant interleukin-2. Pharmacotherapy 14, 635 (1994).
42. M.H. Oppenheim and M.T. Lotze: Interleukin-2: Solid tumor therapy. Oncology 57, 154 (1994).
43. D.R. Parkinson and M. Sznol: High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. Seminars in Oncology 22, 61 (1995).
44. S.S. Taneja, W. Pierce, R. Figlin and A. Belldegrun: Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. Urology 45, 911 (1995).
45. L.T. Vlasveld and E.M. Rankin: Recombinant interleukin-2 in cancer: basic and clinical aspects. Cancer Treatment Reviews 20, 275 (1994).
46. J. Wagstaff, J.W. Baars, G.-J. Wolbink et al.: Renal cell carcinoma and interleukin-2: A review. Eur. J. Cancer 31A, 401 (1995).
47. C. Garbe: Perspectives of cytokine treatment in malignant skin tumors. Recent Results Cancer Res. 139, 349 (1995).
48. R. Whittington and D. Faulds: Interleukin-2, a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46, 446 (1993).
49. S.A. Rosenberg, M.T. Lotze, L.M. Muul et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic cancer. N. Eng. J. Med. 313, 1485 (1985).
50. J.R. Ortaldo, A. Mason and R. Overton: Lymphokine activated killer (LAK) cells: analysis of progenitors and effectors. J. Exp. Med. 164, 1193 (1986).
51. T. Nakarai, M.J. Robertson, M. Streuli et al.: Interleukin 2 Receptor γ Chain Expression on Resting and Activated Lymphoid Cells. J. Exp. Med. 180, 241 (1994).
52. M. Caligiuri, A. Zmiudzinas, T.J. Manley et al.: Functional Consequences of Interleukin-2 Receptor Expression on Resting Human Lymphocytes. J. Exp. Med. 171, 1509 (1990).
53. S.A. Rosenberg, M.T. Lotze, J.C. Yang et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85, 622 (1993).
54. M.J. Koretz, D.H. Lawson, M. York et al.: Randomized study of interleukin-2 (IL-2) vs IL-2 plus lymphokine-activated killer cells for the treatment of melanoma and renal cell cancer. Arch. Surg. 726, 898 (1991).
55. P.A. Palmer, J. Vinke, P. Evers et al.: Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur. J. Cancer 28A, 1038 (1992).
56. S. Legha , M.A. Gianan, C. Plager et al.: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 77, 89 (1996).
57. T.M. Law, R.J. Motzer, M. Madhu et al.: Phase III randomized trial of interleukin-2 with or without lymphokine activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824 (1995).
58. B. Fisher, B.S. Packard, E.J. Read et al.: Tumor localization of adoptively transferred Indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7, 250 (1989).
59. C.D. Platsoucas: Human autologous tumor-specific T-cells in malignant melanoma. Metastasis Rev. 10, 151 (1991).
60. W.C. Pierce, A. Belldegrun and R.A. Figlin: Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal cell carcinoma. Semin. Oncol, 22, 74 (1995).
61. J.A. Thompson, M.C. Benyunes, J.A. Bianco and A. Fefer: Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells. Semin. Oncol. 20, 46 (1993).
62. J.A. Anderson, T.M. Woodcock, J.I. Harty et al.:The effects of pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma. Eur. J. Cancer 31A, 714 (1995).
63. M.R. Albertini, J.A. Sosman, J.A. Hank et al.:The influence of autologous lymphokine activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer 66, 2457 (1990).
64. J.C. Yang, S.X. Topalian, D. Parkinson et al.: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for therapy of metastatic renal cell carcinoma, an interim report. J. Clin. Oncol. 12, 1572 (1994).
65. P. Lissoni, S. Barni, A. Ardizzoia et al.: Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 51, 59 (1994).
66. L.T. VLasveld, S. Horenblas, A. Hekman et al.: Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann. Oncol. 5, 179 (1994).
67. R.P. Whitehead, D. Ward, L. Hemingway et al.: Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res. 50, 6708 (1990).
68. D.T. Sleifer, R.A. Janssen, J. Buter et al.: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol. 10, 1119 (1992).
69. S. Sone and T. Ogura: Local interleukin-2 therapy for cancer, and its effector induction mechanisms. Oncology 51, 170 (1994).
70. P.M. Anderson and M.A. Sorenson: Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet. 27, 19 (1994).
71. P.M. Anderson, E. Katsanis, S.F. Sencer et al.: Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J. Immunother. 12, 19 (1992).
72. F.J. Meyers, C. Paradise, S.A. Scudder et al.: A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. Clinical Pharmacol. and Therap. 49, 307 (1991).
73. L.P. Courtney, J.L. Phelps and L.M. Karavodin: An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology. 28, 223 (1994).
74. R.P. Whitehead, K.D. Friedman and D.A. Clark: A phase I trial of subcutaneous interleukin-2 and interleukin-4. Proc. Ann. Meet. Am. Assoc. Cancer Res. 33, A1381 (1992).
75. Y.C. Yang, L. Owen-Schaub, A. Mendiguren-Rodriquez et al.: Combination immunotherapy for non-small cell lung cancer-results with interleukin-2 and TNFa. J. Thorac. Cardiovasc. Surg. 79, 8 (1990).
76. U. Keilholz, C. Scheibenbogen, P. Brossart et al.: Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma. Recent Results Cane. Res. 139, 383 (1995).
77. M.S. Mitchell: Combining chemotherapy with biological response modifiers in the treatment of cancer. J. Natl. Cancer Inst. 80, 1445 (1988).
78. A.C. Buzaid and S.S. Legha: Combination of chemotherapy with interleukin-2 and interferon-alpha for the treatment of advanced melanoma. Seminars in Oncol. 27, 23 (1994).
79. D.M. Pardoll: Paracrine cytokine adjuvants in cancer immunotherapy, Annu. Rev. Immunol. 13, 399 (1995).
80. J. Triesman, P. Hwu, S. Minamoto, G.E. Shafer et al.: Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85, 139 (1995).
81. P.A. Cassileth, E. Podack, K. Sridhar et al.: Clinical protocol: Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Human Gene Ther. 6, 369 (1995).
82. B. Gansbacher: A pilot study of immunization with IL-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Human Gene Therapy 3, 691 (1992).
83. Clinical Protocols. Cancer Gene Ther. 7, 289 (1994).
84. W. Schmidt, T. Schweighoffer, E. Herbst et al.: Cancer vaccines:The IL-2 dosage effect. Proc. Natl. Acad. Sci. USA 92, 4711 (1995).
85. J.A. Kovacs, M. Basler, R.J. Dewar et al.: Increases in CD4T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N. Engl. J. Med. 332, 567 (1995).
86. Z.P. Bernstein, M.M. Porter, M. Gould et al.: Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86, 3287 (1995).
87. R.G. Hewitt: Interleukin-2: Full circle in a decade. Infect. in Med. July 490 (1994).
88. J.R. Minor: Interleukin-2 in HIV. Am. J. Health-Syst. Pharm. 52, 1345 (1995).
89. M. Howard, J. Farrar, M. Hilfiker et al.: Identification of a T cell derived B-cell growth factor distinct from IL-2. J. Exp. Med. 755, 914 (1982).
90. T. Yokota, T. Otsuka, T. Mosmann et al. Proc. Natl. Acad. Sci. USA 83, 5894 (1986).
91. J. Banchereau, T. Defrance, J.P. Galizzi et al.: Human interleukin 4: Its agonistic and antagonistic effects on B lymphocytes and its receptor. In Cytokines: Basic Principles and Clinical Applications. S. Romagnani, A.K. Abbas (eds). Raven Press: New York 1990, 177-187.
92. M.T. Lotze: Role of IL-4 in the antitumor response. In IL-4 Structure and Function. H. Spits (ed). CRC Press: Boca Raton, 19XX.
93. F.M. Hofman, M. Brock, C.R. Taylor et al.: IL-4 regulates differentiation and proliferation of human precursor B cells. J. Immunol. 141, 1185 (1988).
94. J. Gordon, M.J. Millsum, G.R. Guy et al.: Resting B lymphocytes can be triggered directly through the CDW40(Gp50) antigen. J. Immunol. 140, 1425 (1988).
95. R. Noelle, P.H. Karmmer, J. Ohara et al.: Increased expression of Ia antigen on resting B cells: a new role for B cell growth factor. Proc. Natl. Acad. Sci. USA 81, 6149 (1984).
96. C.M. Snapper, F.D. Finkelman, W.E. Paul: Differential regulation of IgG1 and IgE synthesis by interleukin 4. J. Exp. Med. 767, 183 (1988).
97. X. Han, K. Hoh, C.M. Balch et al.: Recombinant interleukin 4 [RIL-4] inhibits interleukin-2 induced activation of peripheral blood lymphocytes. Lympho. Res. 7, 227 (1988).
98. H. Spits, H. Yssel, X. Paliard et al.: Interleukin 4 inhibits interleukin 2 mediated induction of human lymphokine activated killer cells, but not the generation of antigen specific cytotoxic T lymphocytes in mixed leukocyte cultures. J. Immunol. 141, 29 (1988).
99. S.R. Carding, E.J. Jenkinson, R. Kingston et al.: Developmental control of lymphokine gene expression in fetal thymocytes during T cell ontogeny. Proc. Natl. Acad. Sci. USA 86, 2242 (1989).
100. J. Ransom, M. Fischer, T. Mosmann et al.: Interferon gamma is produced by activated immature mouse thymocytes and reverses the interleukin 4-induced proliferation of immature thymocytes. J. Immunol. 139, 4102 (1987).
101. M.D. Mossalayi, J.C. Lecron, A.H. Dalloul, et al Soluble CD23 (FcE) and interleukin 1 synergistically induce early human thymocyte maturation. J. Exp. Med. 171, 959 (1990).
102. J. Hu-Li, E.M. Sherach, J. Mizuguchi et al.: B cell stimulatory factor I (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J. Exp. Med. 165, 157 (1987).
103. H. Luo, M. Rubio, G. Biron et al.: Anti-proliferative effect of IL-4 in B chronic lymphocytic leukemia. J. Immunol. in press (ref from Spits).
104. M. Bosco, M. Giovarelli , M. Forni et al.: Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently non-immunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145, 3136 (1990).
105. R.I. Tepper, P.K. Pattengale and P. Leder: Murine interleukin 4 displays potent anti-tumor activity in vivo. Cell 57, 503 (1989).
106. E.R. Fearon, D.M. Pardoll, T. Itanya et al.: Interleukin 2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 60, 397 (1990).
107. B. Gansbacher, R. Bannerji, B. Daniels et al.: Retroviral vector-mediated gamma interferon gene transfer into tumor cells generates potent and long lasting anti-tumor immunity. Cancer Res. 50, 7820 (1990).
108. Y. Kawakami, S.A. Rosenberg and M.T. Lotze: Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes for human autologous melanoma. J. Exp. Med. 768, 2183 (1988).
109. M.H. Gilleece, J.H. Scarffe, A. Ghosh et al.: Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections - a phase I dose toxicity trial. Brit. J. Cancer 66, 204 (1992).
110. C.W. Taylor, T.M. Grogan and S.E. Salmon: Effects of interleukin 4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 75, 1114 (1990).
111. F. Herrman, M. Andreeft H.J. Gruss et al.: Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin 6 expression. Blood 78, 2070 (1991).
112. T. Defrance, A.C. Fluckiger, J.-F. Rossi et al.: Antiproliferative effects of interleukin 4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. Blood 79, 990 (1992).
113. T.E. Tanner and G. Tosato: Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6. Blood 79, 452 (1992).
114. J. Van Snick: Interleukin-6: An overview. Annu. Rev. Immunol. 5, 253 (1990).
115. T. Hirano, S. Akira, T. Tetsuya and T. Kishimoto: Biological and clinical aspects of interleukin 6. Immunol. Today 11, 443 (1990).
116. K. Yamasaki, T. Taga, Y. Hirata et al.: Cloning and expression of the human interleukin-6 [BSF-2/IFNb2] receptor. Science 241, 825 (1988).
117. T. Taga, M. Hibi, Y. Hirata et al.: Interleukin-6 triggers the association of its receptor with a possible signal transducer gp130. Cell 58, 573 (1989).
118. T. Ishibashi, H. Kimura, Y. Shikama et al.: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74, 1241 (1989).
119. J. Weber, J.C. Yang, S.L. Topalian et al.: Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. 11, 499 (1993).
120. D. Caracciolo, S.C. Clark and G. Rovera: Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSG. Blood 73, 666 (1989).
121. T. Olencki, G.T. Budd, S. Murthy et al.: Phase IA/IB trial of rhIL-6 in patients with refractory malignancy: hematologic and immunologic effects. Blood Suppl 1, 89a (1992).
122. J.J. Mulé, J.K. McIntosh, D.M. Jablons et al.: In vivo administration of recombinant interleukin-6 mediates tumor regression in mice. J. Exp. Med. 171, 629 (1990).
123. J.J. Mulé, S.G. Marcus, J.C. Yang et al.: Clinical applications of IL-6 in cancer therapy. Res. Immunol. 143, 777 (1992).
124. A. Porgator, E. Tzehoval, A. Katz et al.: IL-6 gene transfection into 3LL tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52, 3679 (1992).
125. C. Scheid, R. Young, R. McDermott et al.: Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol. Immunother. 38, 119 (1994).
126. J. Malejczyk, M. Malejczyk, A. Urbanski and T.A. Luger: Production of natural killer cell activity-augmenting factor (interleukin-6) by human epiphyseal chondrocytes. Arthritis Rheum. 35, 706 (1992).
127. H. Goto, C. Shimazaki, T. Tatsumi et al.: Establishment of a novel myeloma cell line KPMM2 canying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. Leukemia 9, 711 (1995).
128. O.F. Ballester, L.C. Moscinski, G.H. Lyman et al.: High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 83, 1903 (1994).
129. H.J. Gruss, M.A. Brach, R.H. Mertelsmann and F. Herrmann: Interferon-gamma interrupts autocrine growth mediated by endogenous interleukin-6 in renal-cell carcinoma. International J. Cancer 71, 770 (1991).
130. M. Rabau, H. Kashtan, S. Baron et al.: Inhibition of CT-26 murine adenocarcinoma growth in the rectum of mice treated with recombinant human interleukin-6. J. Immunother. Emphasis Tumor. Immunol. 15, 257 (1994).
131. K.W. Moore, P. Vieira, D.F. Florentine et al.: Homology of cytokine synthesis inhibitory factor (IL-10) to Epstein-Barr virus gene BCRF1. Science 248, 1230 (1990).
132. M.R. Walter and T.L. Nagabhushan: Crystal structure of interleukin-10 reveals an interferon gamma-like fold. Biochemistry 34, 12118 (1995).
133. A. Zdanov, C. Schalk-Hihi, A. Gustchina et al.: Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure 3, 591 (1995).
134. Y. Lui, S.H. Wei, A.S. Ho et al.: Expression cloning of the human IL-10 receptor. J. Immunol. 15, 1821 (1994).
135. K.W. Moore, A. O'Garra, M. de Waal et al.: Interleukin-10. Ann. Rev. Immunol. 11, 165 (1993).
136. K. Taga and G. Tosato: IL-10 inhibits T-cell proliferation and IL-2 production. J. Immunol. 748, 1143 (1992).
137. M. de Waal, R.J. Abrams, B. Bennet et al.: Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174, 1209 (1991).
138. W.E. Carson, M.J. Lindemann, R. Baiocchi et al.: The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 85, 3577 (1995).
139. A.E. Chernoff, E.V. Granowitz, L. Shapiro et al.: A randomized, controlled trial of IL-10 in humans. J. Immunol. 154, 5492 (1995).
140. H. Tahara and M.T. Lotze: Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 2, 96 (1995).
141. G. Trinchieri and P. Scott: The role of interleukin 12 in the immune response, disease and therapy. Immunol. Today 15 , 460 (1994).
142. F.D. Finkelman: Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J. Exp. Med. 182, 279 (1995).
143. M.J. Skeen and H.K. Ziegler: Activation of γδT cells for production of IFN-γ is mediated by bacteria via macrophage-derived cytokines IL-1 and IL-12. J. Immunol. 154, 5832 (1995).
144. R.T. Gazzinelli, S. Hayashi, M. Wysocka et al.: Role of IL-12 in the initiation of cell mediated immunity by Toxoplasma gondii and its regulation by IL-10 and nitric oxide. J. Eukaryotic Microbiol. 41, 9S (1994).
145. M. Denis: Interteukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes. Cellular Immunol. 756, 529 (1994).
146. C.L. Nastala, H.D. Edington, T.G. McKinney et al.: Recombinant IL-12 administration induces tumor regression in association with IFN-α production. J. Immunol. 153, 1697 (1994).
147. A. Kelso: Th1 and Th2 subsets: paradigms lost. Immunol. Today 16, 374 (1995).
148. T.A. Wynn, D. Jankovic, S. Hieny et al.: IL-12 exacerbates rather than suppresses T helper 2-dependent pathology in the absence of endogenous IFN-γ. J. Immunol. 154, 3999 (1995).
149. A. D'Andrea, X. Ma, M. Aste-Amezaga et al.: Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: Priming for IL-12 and tumor necrosis factor a production. J. Exp. Med. 181, 537 (1995).
150. T. A. Wynn, D. Kankovic, S. Hieny et al.: IL-12 enhances vaccine-induced immunity to Schisotoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinophilia. J. Immunol. 154, 4701 (1995).
151. S.S. Hall: IL-12 at the crossroads. Science 268, 1432 (1995).
152. C.M. Bacon, D.W. McVicar, J.R. Ortaldo et al.: Interleukin-12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differntial use of Janus family tyrosine kinases by 11-2 and IL-12. J. Exp. Med. 181, 399 (1995).
153. K.H. Grabstein, J. Eisenman, K. Shanebeck et al.: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264, 965 (1994).
154. J.G. Giri, M. Ahdieh, J. Eisenmann et al.: Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13, 2822 (1994).
155. J. Giri, S. Kumaki, M. Ahdieh et al.: Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 14, 3654 (1995).
156. R.J. Armitage, B.M. Macduff, J. Eisenman et al.: IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol. 15, 483 (1995).
157. W.M. Lewko, T.L. Smith, D.J. Bowman et al.: Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother. 10, 13 (1995).
158. W. Munger, S.Q. DeJoy, R. Jeyaseelan Sr. et al.: Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2. Cellular Immunol. 165, 289 (1995).
159. L.S. Quinn, K.L. Haugk and K.H. Grabstein: Interleukin-15: A novel anabolic cytokine for skeletal muscle. Endocrinology 126, 3669 (1995).
160. E.C. Borden: Interferons. In: Cancer Medicine. J.F. Holland et al. (eds). 1993. Lea & Feabiger: Philadelphia.
161. S.E. Grossberg: Interferons: an overview of their biological and biochemical properties. In Mechanism of Interferon Actions, L.M. Pfeffer (ed). 1987. CRC Press, Inc: Boca Raton, p. 137.
162. A.A. Branca and C. Baglioni: Evidence that types I and II interferons have different receptors. Nature 294, 768 (1981).
163. M. Aguet, Z. Dembic and G. Merlin: Molecular cloning and expression of the human interferon-g receptor. Cell 55, 273 (1988).
164. R.D. Schreiber and M.A. Farrar: The biology and biochemistry of interferon-gamma and its receptor. Gastroenterol. Jpn. 4, 88 (1993).
165. J.L. Pace and S.W. Russell: Activation of mouse macrophages for tumor cell killing. Quantitave analysis of interactions between lymphokine and lipopolysaccharide. J. Immunol. 126, 1863 (1981).
166. L. Reid, N. Minato, I. Gresser et al.: Influence of antimouse interferon serum on the growth and metastasis of tumor cells persistently infected by virus and of human prostatic tumors in athymic mice. Proc. Natl. Acad. Sci. 78, 1171 (1981).
167. I. Gresser, F. Belardelli, C. Maury et al.: Injection of mice with antibody to interferon enhances the growth of murine transplantable tumors. J. Exp. Med. 158, 2095 (1983).
168. A.E. Maluish: Effects of recombinant interferon-alpha on immune function in cancer patients. J. Biol. Response Mod. 2, 470 (1983).
169. M. Fellous, U. Nir, D. Wallach et al.: Interferon-dependent induction of mRNA for the major histocompatability antigens in human fibroblasts and lymphoblastoid cell lines. Proc. Natl. Acad. Sci. 79, 3082, 1982.
170. R.C. van Schie, H.G. Verstraten, W.J. Tax et al.: Effect of rIFN-gamma on antibody-mediated cytotoxicity via human monocyte IgG Fc receptor II (CD32). Scand. J. Immunol. 36, 385 (1992).
171. A.A. te Velde, R. de Waal Malefijt, R.J. Huijbens et al.: IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J. Immunol. 149, 4048 (1992).
172. W.M. Vuist, M.J. Visseren, M. Otsen et al.: Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha. Cancer Immunol. Immunother. 36, 163 (1993).
173. V. Jendrossek, A.M. Peters, S. Buth et al.: Improvement of Superoxide production in monocytes from patients with chronic granulomatous disease by recombinant cytokines. Blood 81, 2131 (1993).
174. M.J. Robertson, T.J. Manley, C. Donahue et al.: Costimulatory signals are required for optimal proliferation of human natural killer cells. J. Immunol. 150, 1705 (1993).
175. M.J. Robertson and J. Ritz: Biology and clinical relevance of human natural killer cells. Blood 76, 2421 (1990).
176. J.R. Wunderlich and R.J. Hodes: Principles of Tumor Immunity: Biology of Cellular Immune Responses, in: Biologic Therapy of Cancer, V.T. Devita, S. Hellman, S.A. Rosenberg (eds). 1991. J. B. Lippincott: New York. p. 14.
177. N. Minato, L. Reid, H. Cantor et al.: Mode regulation of natural killer cell activity by intereferon. J. Exp. Med. 152, 124 (1980).
178. C. Losinno, B.D. Wines, T.G. Johns et al.: Natural killer cell activity against cultured melanoma cells: a dye-reduction technique with studies on augmented activity by interferon subtypes. Nat. Immun. 11, 215 (1992).
179. M.A. Giedlund, H. Orn and H. Wigzell: Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 273, 759 (1987).
180. E. Saksela, T. Timonen and K. Cantell: Cellular Interactions in the augmentation of human NK activity by interferon. Ann. N.Y. Acad. Sci. 350, 102 (1980).
181. R.M. Welsh, K. Karre, M. Hansson et al: Interferon-mediated protection of normal and tumor target cells against lysis by mouse natural killer cells. J. Immunol. 1, 219 (1981).
182. C. Garbe and K. Krasagakis: Effects of interferons and cytokines on melanoma cells. J. Invest. Derm. 100, 239S (1993).
183. H. Matsuyama, S. Yoshihiro, Y. Ohmoto et al.: Direct and indirect effects of human interferon alpha on renal cell carcinoma: a new in vitro assay system for evaluating cytokine-mediated antitumor effects. Cancer Immunol. Immunother. 37, 84 (1993).
184. Z. Reiter, S. Tomson, O.N. Ozes et al.: Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation. Blood 81, 1699 (1993).
185. E.F. Meurs, J. Galabru, G.N. Barber et al.: Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. 90, 232 (1993).
186. R. Godbout, J. Miyakoshi, K.D. Dobler et al.: Lack of expression of tumor-suppressor genes in human malignant glioma cell lines. Oncogene 7, 1879 (1992).
187. O.I. Olopade, D.L. Buchhagen, K. Malik et al.: Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 55 (Suppl. 10), 2410 (1993).
188. C. Natoli, C. Garufi, N. Tinari et al.: Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. Br. J. Cancer 67, 564 (1993).
189. R.L. Scher, W.M. Koch and W.J. Richtsmeier: Induction of the intercellular adhesion molecule (ICAM-1) on squamous cell carcinoma by interferon gamma. Arch. Otolaryngol. Head Neck Surg. 119, 432 (1993).
190. H. Takahashi, Y. Okai, R.J. Paxton et al.: Differential regulation of carcinoembryonic antigen and biliary glycoprotein by gamma-interferon. Cancer Res. 53, 1612 (1993).
191. N. Weidner, J.P. Semple, W.R. Welch et al.: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1 (1991).
192. N. Weidner, J. Folkman, F. Dozza et al.: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma [see comments]. J. Natl. Cancer Inst. 84, 1875 (1992).
193. I. Saiki, K. Sato, Y.C. Yoo et al.: Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). Intl. J. Cancer 57, 641 (1992).
194. J. Folkman and D. Ingber: Inhibition of angiogenesis. Semin. Cancer Biol. 3, 89 (1992).
195. C.W. White: Treatment of hemangiomatosis with recombinant interferon alfa. Semin. Hematol. 27, 15 (1990).
196. R.K. Maheshwari, V. Srikantan, D. Bhartiya et al.: Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. J. Cell. Physiol. 146, 164 (1991).
197. D.C. Billington: Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases. Drug Des. Discov. 8, 3 (1991).
198. J.R. Quesada, J. Reuben, J.T. Manning et al.: Alpha interferon for the induction of remission in hairy-cell leukemia. N. Engl. J. Med. 310, 15 (1984).
199. R. Dadmarz, T. Evans, D. Secher et al.: Hairy cells possess more interferon receptors than other lymphoid cell types. Leukemia 1, 357 (1987).
200. J.D. Scharzmeier, M. Schwabe, L. Wagner et al.: Effect of alpha-2-interferon on hairy cells and cell lines. A role for type I interferon receptors and RNA synthesis. Leukemia 1, 361 (1987).
201. M. Talpaz, H.M. Kantarjain, K.B. McCerdie et al.: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69, 1280, (1987).
202. R. Kurzrock, M. Talpaz, H.M. Kantarjain et al.: Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70, 943 (1987).
203. B. Maxwell, M. Talpaz and J.U. Gutterman: Down regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN) therapy. Intl. J. Cancer. 56, 23 (1985).
204. M. Rosenblum, B. Maxwell, M. Talpaz et al.: In vitro sensitivity and resistance of chronic myelogenous leukemia cells to alpha interferon: Correlation with receptor binding and induction of 2′5′ oligoadenylate synthetase. Cancer Res. 46, 4848 (1986).
205. E. Knight, Jr., E.D. Anton, D. Fahey et al.: Interferon regulates c-myc gene expression in Daudi cells at the post-transcriptional level. Proc. Natl. Acad. Sci. USA 82, 1151 (1985).
206. J.R. Quesada, D.A. Swanson, A. Trindade et al.: Renal Cell Carcinoma: Antitumor effects of leukocyte interferon. Cancer Res. 43, 940 (1983).
207. J.M. Kirkwood, J.E. Harris, R. Vera et al.: A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: The American Cancer Society Collaborative Trial. Cancer Res. 45, 863 (1985).
208. T. Umeda and T. Niijima: Phase II study of alpha interferon on renal cell carcinoma. Cancer 58, 1231 (1986).
209. H.B. Muss, J.J. Costanzi, R. Leavitt et al.: Recombinant alfa interferon in renal cell carcinoma: A randomised trial of two routes of administration. J. Clin. Oncol. 5, 286 (1987).
210. Figlin, R.A., J.B. deKernion, E. Mukamel et al.: Recombinant interferon alfa-2a in metastatic renal cell carcinoma. J. Clin. Oncol. 6, 1604 (1988).
211. D. Vugrin, L. Hood, W. Taylor and J. Laslo: Phase II study of human lymphoblastoid Interferon in patients with advanced renal carcinoma. Cancer Treat. Reports 69, 817 (1985).
212. E.T. Creagan, J.C. Buckner, R.G. Hahn et al.: An evaluation of recombinant leucocyte interferon with aspirin in patients with metastatic renal cell cancer. Cancer 61, 1787 (1988).
213. R.L. Miller, R.G. Stess, J.W. Clark et al.: Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 49, 1871 (1989).
214. S.D. Fossa, G. Lehne, R. Gunderson et al.: Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies. Intl. J. Cancer 50, 868 (1992).
215. T.F. Logan, M.S. Ernstoff, J.M. Kirkwood, B. Gerich, D. Friberg, T. Whiteside, B. Eddy, P. Witman, J. Schindler, R.B. Herberman and S. Reich: Changes in natural killer cell (NK) phenotype in peripheral blood (PB) of patients (PT) with renal cell carcinoma and melanoma treated with recombinant interferon gamma (IFN-gamma). Proc. Am. Assoc. Cancer Res. 78, 2520A (1987).
216. M.B. Garnick, S.D. Reich and B.E.A. Maxwell: Phase FII study of recombinant interferon gamma in advanced renal cell carcinoma. J. Urol. 139, 251 (1988).
217. J.R. Quesada, R. Kurzrock, S.A. Sherwin et al.: Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J. Biol. Response Mod. 6, 20 (1987).
218. J.J. Rinehart, L. Malspeis, D. Young et al.: Phase I/II Trial of human recombinant interferon gamma in renal cell carcinoma. J. Biol. Response Mod. 5, 300 (1986).
219. U. Otto, S. Conrad, A.W. Schneider et al.: Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Drug Res. 38, 1658 (1988).
220. W. Aulitzky, G. Gastl, W.E. Aulitzky et al.: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J. Clin. Oncol. 7, 1875 (1989).
221. U. Bruntsch, P.H. de Mulder, W.W. ten Bokkel Huinink et al.: Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma. J. Biol. Response Mod. 9, 335 (1990).
222. C.W. Czarniecki, C.W. Fennie, D.B. Powers et al.: Synergistic antiviral and antiproliferative activities of E coli derived human alpha, beta and gamma interferons. J. Virol. 49, 490 (1984).
223. K. Foon, J. Doroshow, E. Bonnem et al.: A prospective randomized trial of alpha2b interferon/gamma interferon or the combination in advanced metastatic renal cell carcinoma. J. Biol. Response Mod. 7, 540 (1988).
224. J.R. Quesada, L. Evans, S.R. Saks et al.: Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. J. Biol. Response Mod. 7, 234 (1988).
225. M.S. Ernstoff, S. Nair, R.R. Bahnson et al.: A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 8, 1637 (1990).
226. M.S. Ernstoff, W. Gooding, S. Nair et al.: Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 52, 851 (1992).
227. J.P. Kuebler, G.A. Godette, D.J. Bock et al.: Synergistic effects of vinblastine and recombinant interferon-beta on renal tumor cell lines. J. Interferon Res. 10, 281 (1990).
228. R. A. Figlin, J.B. deKernion, J. Maldazys et al.: Treatment of renal cell carcinoma with alpha(human leukocyte) interferon and vinblastine in combination: A phase I-II trial. Cancer Treat. Reports 69, 263 (1985).
229. S.D. Fossa and S.T. de Garis: Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: a progress report. Intl. J. Cancer Suppl 1, 36 (1987).
230. M.R. Sertoli, I. Brunetti, A. Ardizzoni et al.: Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am. J. Clin. Oncol. 12, 43 (1989).
231. S.D. Fosså, N. Raabe and B. Moe: Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study. Br. J. Urol. 64, 468 (1989).
232. S. Palmeri, V. Gebbia, A. Russo et al.: Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma. Tumori 76, 64 (1990).
233. D.L. Trump, P.M. Ravdin, E.C. Borden et al.: Interferon-alpha-nl and continuous infusion vinblastine for treatment of advanced renal cell carcinoma. J. Biol. Response Mod. 9, 108 (1990).
234. L.P. Kellokumpu and E. Nordman: Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study. J. Biol. Response Mod. 9, 439 (1990).
235. M. Rizzo, R. Bartoletti, C. Selli et al.: Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma. Eur. Urol. 16, 271 (1989).
236. O. Merimsky and S. Chaitchik: Interferon plus vinblastine in renal carcinoma patients who had failed on interferon alone [letter]. Eur. J. Cancer 26, 8 (1990).
237. O. Merimsky, B.I. Shnider and S. Chaitchik: Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma? Mol. Biother. 3, 34 (1991).
238. A. Sella, C.J. Logothers, K. Fitz et al.: Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J. Urol. 147, 573 (1992).
239. H.J. Konig, W. Gutmann and J. Weissmuller: Ifosfamide, vindesine and recombinant alpha-interferon combination chemotherapy for metastatic renal cell carcinoma. J. Cancer Res. Clin. Oncol. 117, S221 (1991).
240. A. Falcone, C. Cianci, S. Ricci et al.: Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study. Cancer Diag. Treat. Res. 72, 564 (1993).
241. H.B. Muss: Renal Cell Carcinoma. In: Biologic Therapy of Cancer, V.T. Devita, S. Hellman, S.A. Rosenberg (eds). 1991. J.B. Lippincott: New York. p. 298-309.
242. L.M. Minasian, R.J. Motzer, L. Gluck et al.: Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11, 1368 (1993).
243. S.E. Salmon, B.G. Durie, L. Young et al.: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J. Clin. Oncol. 1, 217 (1983).
244. P.P. Trotta and S.D. Harrison, Jr.: Evaluation of the anti-tumor activity recombinant human gamma interferon employing human melanoma xenografts in athymic nude mice. Cancer Res. 47, 5347 (1987).
245. M.S. Ernstoff, D. Chee, G. Witman et al.: The expression of p97, kd250, DR and beta-2 microglobulin cell surface antigen in cycling melanoma cells in culture (Abstract). Clin. Res. 32, 345A (1984).
246. J.M. Kirkwood and M.S. Ernstoff: Melanoma: therapeutic options with recombinant interferons Semin. Oncol. 12, 7 (1985).
247. J.M. Kirkwood, M.H. Stawderman, M.S. Ernstoff et al.: Interferon alpha-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST1684. J. Clin. Oncol. 14, 7 (1996).
248. B. Beutler, D. Greenwald, J.D. Hulmes et al: Identity of tumour necrosis factor and the macrophage-secreted factor 'cachectin'. Nature 316, 552 (1985).
249. K.J. Tracey and A. Cerami: Tumor necrosis factor: an updated review of its biology. Crit .Care Med. 21 (10 Suppl), S415 (1993).
250. A.S. Dofferhoff, E. Vellenga, P.C. Limburg et al.: Tumour necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature. Nether. J. Med. 39, 45 (1991).
251. K.J. Tracey and A. Cerami: Metabolic responses to cachectin/TNF. A brief review. Ann. NY. Acad. Sci. 587, 325 (1990).
252. P. Vassalli: The pathophysiology of tumor necrosis factor. Ann. Rev. Immunol. 10, 411 (1992).
253. B.B. Aggarwal and J. Vilcek (eds.): Tumor Necrosis Factor: Structure, Function and Mechanisms of Action. 1992. New York: Marcel Dekker.
254. E. Ottaviani, E. Caselgrandi and C. Franceschi : Cytokines and evolution: in vitro effects of IL-1 alpha, IL-1 beta, TNF-alpha and TNF-beta on an ancestral type of stress response. Biochem. Biophys. Res. Commun. 207, 288 (1995).
255. D. Adamthwaite and M.A. Cooley : CD8+ T-cell subsets defined by expression of CD45 isoforms differ in their capacity to produce IL-2, IFN-gamma and TNF-beta. Immunol. 81, 253 (1994).
256. C. Jassoy, T. Harrer, T. Rosenthal et al.: Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens. J. Virol. 67, 2844 (1993).